Unichem has obtained tentative approval from the Food and Drug Administration for sitagliptin tablets in dosage strengths of 25 mg, 50 mg, and 100 mg The medication is a generic of Merck Sharpe and ...

(Reuters) - Details of a large heart safety study presented on Monday appear to give Merck and Co's diabetes drug Januvia a clean bill of health, possibly setting the stage for a return to sales ...

After years of battling over the patents on blockbuster diabetes drug Januvia, Merck and its generic rival Viatris are ready to put the case to rest. In a recent filing with the U.S. District Court ...

DEAR DR. ROACH: Is Januvia an effective drug for diabetes? What are the side effects? — M.A.A. ANSWER: Sitagliptin (Januvia) is an oral medication for diabetes mellitus. The way it works is ...

NEW YORK, Oct 17 (Reuters) - Merck & Co said on Wednesday U.S. regulators have approved use of its Januvia diabetes drug in new combinations with other treatments, but noted reports of serious ...

In one quick announcement Monday, Merck's ($MRK) diabetes drug Januvia became the drug to beat in its class. New study data could boost Januvia's sales by 10% in 2020 ...

NEW YORK (AP) -- Merck & Co. has disclosed that it is ending development of a pill that combines its diabetes drug Januvia with atorvastatin, the main ingredient in Lipitor. Merck cited unspecified ...

Medicare Part D prescription drug plans generally cover prescription drugs like Januvia, which, along with diet and exercise, helps lower blood sugar for people with type 2 diabetes. The cost of ...

New data reveals that Januvia was as effective as Glucotrol in reducing blood sugar levels in patients with type 2 diabetes.Merck (NYSE: MRK) announced today its drug Januvia was as effective as the ...

Januvia, a widely used diabetes drug that generates $6 billion in annual sales for maker Merck, does not increase patients’ risk of being hospitalized for heart failure, a risk that did show up in ...

Big savings are coming in 2026. See the list of the first 10 drugs with prices negotiated by Medicare, including Eliquis, ...

Merck said Thursday it closed out the fourth quarter of 2011 with $12.3 billion in sales, a 2% increase from $12 billion in the same period in 2010. While that missed the Street’s consensus for the ...